113 related articles for article (PubMed ID: 11135462)
1. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
[TBL] [Abstract][Full Text] [Related]
2. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
[TBL] [Abstract][Full Text] [Related]
3. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
Zendehrokh N; Dejmek A
Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
[TBL] [Abstract][Full Text] [Related]
4. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
Nagel H; Schlott T; Schulz GM; Droese M
Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
[TBL] [Abstract][Full Text] [Related]
5. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
Adell E; Dejmek A
Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
[TBL] [Abstract][Full Text] [Related]
7. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
Zendehrokh N; Rehnberg J; Dejmek A
Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity in pleural effusions: diagnostic significance.
Yang CT; Lee MH; Lan RS; Chen JK
J Clin Oncol; 1998 Feb; 16(2):567-73. PubMed ID: 9469342
[TBL] [Abstract][Full Text] [Related]
9. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
10. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of human telomerase reverse transcriptase mRNA in malignant pleural effusions: A preliminary report for in situ hybridization detection.
Shu J; Sun GY; Liu AP; Liu J
Clin Chim Acta; 2007 Jun; 381(2):131-5. PubMed ID: 17399696
[TBL] [Abstract][Full Text] [Related]
12. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic implications of telomerase activity in pleural effusions.
Dikmen G; Dikmen E; Kara M; Sahin E; Doğan P; Ozdemir N
Eur Respir J; 2003 Sep; 22(3):422-6. PubMed ID: 14516130
[TBL] [Abstract][Full Text] [Related]
14. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in effusion cytology.
Hiroi S; Nakanishi K; Kawai T
Diagn Cytopathol; 2003 Oct; 29(4):212-6. PubMed ID: 14506674
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions.
Rosolen DC; Kulikowski LD; Bottura G; Nascimento AM; Acencio M; Teixeira L; Vargas FS; Sales RK; Antonangelo L
Lung Cancer; 2013 Jun; 80(3):284-8. PubMed ID: 23453645
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
[TBL] [Abstract][Full Text] [Related]
17. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
Nieh S; Chen SF; Fu E; Jan CI; Lee WH
Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
[TBL] [Abstract][Full Text] [Related]
18. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
19. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
20. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]